AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 202 min read$MYGN

Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He

Myriad Genetics (MYGN) shares rose 20% premarket after announcing the sale of its Prenatal Health division to Labcorp for $210M. Labcorp expects $160M in first-year revenue from the acquisition. MYGN's P/S ratio is 0.49, below historical and industry averages, reflecting market skepticism about growth. The company's GF Score is 47, indicating moderate financial health with weak growth and profitability.

Original reporting
gurufocus.com
Published Oct 20, 2026, 2:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 2:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$MYGN
Bullish
high confidence
Mentioned
$MYGN
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$MYGNBullishHigh
01

Why it matters

The transaction provides immediate cash, reduces exposure to a loss‑making segment, and is expected to modestly improve earnings by year two, prompting a strong pre‑market price reaction.

02

Market read

The deal is material for MYGN, driving a >20% pre‑market surge and offering a clear short‑term trading opportunity.

03

What to watch

Potential regulatory delays for the deal and the loss of a revenue‑generating division could hurt future growth beyond the short‑term cash boost.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Myriad Genetics (MYGN) is a molecular diagnostics company with ongoing losses; the sale of its Prenatal Health unit to Labcorp for $210 M is its first major divestiture.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Myriad Genetics announced a $210 million cash divestiture of its Prenatal Health testing division to Labcorp, driving a >20% pre‑market rally.

Expected impact

upward pressure as the market prices in the cash inflow and earnings accretion by year two.

Evidence & confidence

A sizable cash transaction for a micro‑cap with ongoing losses is material; the pre‑market price jump confirms market reaction.

Market effects

Sector

The divestiture may sharpen focus on Myriad's core oncology and women's health diagnostics, potentially improving sector margins.

Regional

US biotech micro‑caps could see heightened attention as investors reassess cash‑rich, loss‑making firms.

Global

Limited to US‑listed diagnostics space; no broader macro impact.

Counterpoint

What could challenge this read

The cash proceeds may be insufficient to offset long‑term structural challenges; the stock could face pressure once the initial rally fades.

Key entities

  • company
    Myriad Genetics Inc

    Seller of the Prenatal Health testing division.

  • company
    Labcorp

    Buyer of the Prenatal Health testing division.

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

5 outlets

Related articles

OCT 20
$MYGNMed

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

financialcontent.com2 min
OCT 20
$LHMedAI 8/10

Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln

LabCorp (LH) will acquire Myriad Genetics' (MYGN) prenatal testing business for $210M in cash plus inventory value. The deal includes products like Prequel and Foresight. LabCorp expects $160M in revenue the first year and slight earnings accretion. Myriad plans to invest proceeds in cancer care. The transaction is expected to close by early 2027.

rttnews.com2 min
OCT 20
$MYGNHighAI 9/10

Why is Myriad Genetics stock surging today?

Myriad Genetics (MYGN) stock rose 21.4% in pre-market trading after announcing the sale of its Prenatal Health Testing Business to Labcorp for $210M in cash. The deal, expected to close by early 2027, includes four prenatal tests. CEO Sam Raha stated the transaction will boost revenue growth, profitability, and balance sheet strength, focusing on cancer care. The move follows a 16% year-over-year decline in prenatal revenue and a guidance cut.

investing.com2 min